Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Researcher from NIH (National Institute of Neurological Disorders and Stroke) recently finds a mystery over Diabetes drug and suggests drug may restrict recurrent stroke in patients with immune resistance.
Pioglitazone type of drug used in Diabetes patients may prevent stroke in diabetes, the research may be use full in preventing heart attacks in patients who already had one stroke earlier. This novel work of Insulin Resistance Intervention after stroke published in International Stroke Conference 2016 in Los Angeles and also published in New England Journal of Medicine.
rn
"This study represents a novel approach to prevent recurrent vascular events by reversing a specific metabolic abnormality thought to increase the risk for future heart attack or stroke," said Walter J. Koroshetz, M.D., director of the NINDS.
In the appropriate study Pioglitazone also reduce the risk of over 52% in patients used in study.
Note: The above story is for information purpose only, for more information go through original story source.
Story Source: NIH (National Institute of Neurological Disorders and Stroke)
Journal References
Walter N. Kernan, Catherine M. Viscoli, Karen L. Furie, Lawrence H. Young, Silvio E. Inzucchi, Mark Gorman, Peter D. Guarino, Anne M. Lovejoy, Peter N. Peduzzi, Robin Conwit, Lawrence M. Brass, Gregory G. Schwartz, Harold P. Adams, Leo Berger, Antonio Carolei, Wayne Clark, Bruce Coull, Gary A. Ford, Dawn Kleindorfer, John R. O’Leary, Mark W. Parsons, Peter Ringleb, Souvik Sen, J. David Spence, David Tanne, David Wang, Toni R. Winder. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine, 2016; 160217112012002 DOI: 10.1056/NEJMoa1506930